We translate research, protocols, and clinical data into clear, compassionate language. We show our process. We show our credibility. We show the level of care behind every step.

The long-term efficacies in individuals who have responded to this treatment modality are not yet fully known. Emerging evidence indicates that some individuals remain well for several months. Undoubtedly, there will be some individuals who remain well for longer periods of time. It’s also known that other individuals will require booster sessions to maintain their feelings of wellness. The booster sessions are typically administered approximately once per month, depending on the chosen molecule.

This depends on the drug and will be assessed by our physicians during the intake process. Generally:

• Any individual who has a primary diagnosis is anything other than MDD or BD. As noted above, individual consideration will be given on a case-by-case basis for adults with either PTSD or OCD.
• Individuals who meet DSM-5 criteria for a substance use and or alcohol use disorder
• Any individual who has met DSM-5 criteria for a Substance Use Disorder and/or alcohol use disorder in the past 3 months.
• All individuals who use illicit substances (but do not meet criteria for Substance Use Disorder according to the DSM-5 criteria) must refrain from using substances for a minimum of one month prior to their first infusion at Braxia Health.
• Individuals who are experiencing psychotic symptoms as part of an MDE (mood congruent/mood incongruent)
• Individuals with a dementing disorder (e.g., Alzheimer’s disease)
• Individuals who are unable to provide written consent to the treatment
• Individuals who are unable to adhere to the protocol in its totality (i.e., remain in the clinic post infusion for a minimum of 20 minutes or as advised by the medical team for observation).
• Individuals who are unable to identify a person to ensure their safe transport to home post infusion
• Individuals with symptomatic traumatic brain injury
• Uncontrolled medical disorders (i.e., uncontrolled and/or insufficiently treated hypertension, allergies to the drug and/or previous intolerability of the drug)
• Pregnancy
• Medical contraindications to the molecule (e.g. epilepsy)
• Patients that are over 275 lbs.
• Patients who do not adhere to Braxia Health protocol with respect to chaperoning during the visit and post-discharge
• Individuals will be ineligible for treatment if they are not a Canadian resident
• Any patient who does not have a community MRP will not be accepted for assessment or any procedure at Braxia Health.
• Any individual who exhibits aggressive or intimidating behaviour towards Braxia Health staff or other patients will not be eligible for treatment at Braxia Health.
• Any patient who does not adhere to all pre-procedure recommendations (e.g., food fasting) is not eligible for treatment at Braxia Health.
• Patients feeling acutely unwell for any reason (e.g. symptoms of infection) and/or have come into direct contact with someone acutely ill from a transmissible infection.